Targeting anoikis-related genes, particularly MMP9, enhances anoikis sensitivity and reduces RCC invasiveness, offering a potential therapeutic strategy to mitigate metastasis and improve clinical outcomes. This evidence concerns the gene MMP9 and renal cell carcinoma.